• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

atopic dermatitis

Biotech

Vyne to reevaluate pipeline after eczema fail uproots plans

Vyne’s lead asset has failed to improve the severity of atopic dermatitis, uprooting the biotech’s plans and sending the stock plummeting.
Gabrielle Masson Aug 10, 2022 11:23am

Amgen hits pause on $400M eczema bet to tweak phase 3 study

Aug 4, 2022 7:00am

Evelo Biosciences pauses dermatitis drug after trail failure

Apr 14, 2022 11:45am

Lilly’s $1B bet yields 'compelling' data on Dupixent rival

Mar 28, 2022 7:40am

J&J ends work on eczema drug, a $610M dent to ex-XBiotech asset

Feb 2, 2022 5:42pm

Novartis JAKs in rival to Incyte after seeing clinical data

Feb 2, 2022 7:30am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy